



RaQualia
innovators for life

5-HT_{2B} Antagonist: RQ-00310941 for Irritable Bowel Syndrome (IBS)

Worldwide Partnering Opportunity

RaQualia Pharma Inc.

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011

1. Summary

- 5-HT_{2B} receptor is an attractive drug target for the treatment of D-IBS ¹⁾
- 5-HT_{2B} antagonist exhibited efficacy in a TNBS-induced visceral hypersensitivity model in rats ²⁾
- 5-HT_{2B} antagonist significantly inhibited stress induced abnormal defecation, but did not have an affect on normal defecation in rats
- 5-HT_{2B} antagonist normalized the increased colonic motility and impaired colonic compliance in TNBS-sensitized rats
- Orally active, potent and selective 5-HT_{2B} antagonists have been discovered and patent filed in 2008
- RQ-00310941 was selected as a potential candidate, and profiling is ongoing to nominate a development candidate in 2010

1) D-IBS: Diarrhea Predominant Irritable Bowel Syndrome

2) TNBS: 2,4,6-Trinitrobenzene Sulfonic Acid

2. Table of Contents

Title	Slide No.
1. Summary	2
2. Table of Contents	3
3. Product Concept	4
4. Unmet Medical Needs	5
5. Market Opportunity	6
6. Rationale	7
7. Compound Attributes	14
8. Competitors	25

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011